access to human body samples by another existing cohort

The response rate of immune checkpoint inhibitors remains relatively low and the identification of the new predictive biomarkers is necessary. The rare population of cDC1 is very interesting, as its mouse counterparts is essential for the cross presentation of tumor-associated antigens, tumor immunity and response to immunotherapies. Their role in humans has not been studied. This proposal aims to study the prognostic role of cDC1 in a cohort of patients with advanced NSCLC, possibly demonstrating their positive predictive value of immune checkpoint inhibitors response.

Multicenter study aiming to collect patient's clinical data retrospectively and their histological samples prospectively.

The cohort will include:

• 30 patients PD-L1 > 50% treated with pembrolizumab in first line and having a progression free survival ≥ 3 months
• 30 patients PD-L1 > 50% treated with pembrolizumab in first line and having a progression free survival < 3 months
• 30 patients PD-L1 < 50% treated with cisplatin-based chemotherapy in first line

Inclusion Criteria:

• NSCLC diagnosis
• Advanced disease (Stage III-IV) according to the TNM 7th/8th classification
• Patients have to have performed pembrolizumab in first line if PD-L1 ≥ 50% or cisplastin-based chemotherapy if PD-L1 < 50%
• FFPE material available from diagnostic sample

Exclusion Criteria:

-

Retrospective cohort of pembrolizumab or cisplatin-based chemiotherapy treated patients performing these regimens in first-line according to their PD-L1 score